Could Personalizing Multimodal Interventions Give Them Oomph?
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
Gantenerumab Mystery: How Did It Lose Potency in Phase 3?
In the Graduate trials, the anti-amyloid antibody gantenerumab cleared only half as much plaque as it had done in earlier studies. Is formulation or dosing to blame?
As Parkinson’s Progresses, Do Synuclein Fibrils Shape-Shift?
Conformers amplified from CSF of late-stage PD adopt distinct folds and trouble neurons.
Donanemab Mops Up Plaque Faster Than Aduhelm
In a head-to-head comparison, donanemab banished four times as much plaque in the first six months as aducanumab did, partly due to its faster titration.
In Small Trial, Gene Therapy Spurs ApoE2 Production
ApoE2 was detected in cerebrospinal fluid of ApoE4 carriers with Alzheimer’s disease who received a virus expressing the protective allele.
Introducing Alzforum Database of 137 APOE Gene Variants
Adding to our collection of APP, Presenilin, Tau, and Trem2 mutations, the new dataset curates neurologic and non-neurologic information, ranging from clinical to molecular.
Cognitive Tests Taken at Home Are on Par with In-Clinic Assessments
Six commonly used tests accurately detected dementia, even preclinical cognitive slippage, when given over video chat or face-to-face.
Two New Stabs at Vaccinating People Against Pathologic Tau
A liposomal anti-tau vaccine elicited a response against disease-linked forms of tau, outdoing a conjugated vaccine. A separate tack to vaxx against tau is waiting in the wings.
Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial
In Phase 3 trials, the drug reduced agitation more than placebo; however, both groups benefited substantially.
Dare We Say Consensus Achieved: Lecanemab Slows the Disease
Scientists at CTAD found the Phase 3 trial well-done, the data consistent, and expect the drug to be approved. Priorities: grow the effect, understand the bleeding risk.
Clinical Trials on Alzheimer's Disease (CTAD) 2022
Dare We Say Consensus Achieved: Lecanemab Slows the Disease Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial Two New Stabs at Vaccinating People Against Pathologic Tau Cognitive Tests Taken at Home Are on Par with In-Clinic Assess
Dystrophic Neurites Dampen Long-Range Neuronal Signaling
These axonal swellings block action potentials, weakening neural networks in mice. PLD3, an Alzheimer’s disease risk gene, may be involved.
Finally, a Biomarker to Distinguish Primary Tauopathies?
In two primary tauopathies, fragments containing tau’s microtubule-binding region drop in the CSF as they accumulate in the brain.
Bassoon Heralds Spread of Toxic Tau
Knocking down the synaptic scaffolding protein in mice eased neurofibrillary tangles, gliosis, and neurodegeneration.
Rare Variants in Lipid Transporter Genes Increase Risk for Alzheimer’s Disease
Along with previously identified rare variants in TREM2, SORL1, and ABCA7, a massive exome sequencing effort identified variants in ATP8B4 and ABCA1.
Current Filters
No filters selected